Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 74


The natural human IgM antibody PAT-SM6 induces apoptosis in primary human multiple myeloma cells by targeting heat shock protein GRP78.

Rasche L, Duell J, Morgner C, Chatterjee M, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S.

PLoS One. 2013 May 7;8(5):e63414. doi: 10.1371/journal.pone.0063414.


Early development of PAT-SM6 for the treatment of melanoma.

Hensel F, Eckstein M, Rosenwald A, Brändlein S.

Melanoma Res. 2013 Aug;23(4):264-75. doi: 10.1097/CMR.0b013e328362cbc8.


The anti-cancer IgM monoclonal antibody PAT-SM6 binds with high avidity to the unfolded protein response regulator GRP78.

Rosenes Z, Mulhern TD, Hatters DM, Ilag LL, Power BE, Hosking C, Hensel F, Howlett GJ, Mok YF.

PLoS One. 2012;7(9):e44927. doi: 10.1371/journal.pone.0044927.


GRP78-directed immunotherapy in relapsed or refractory multiple myeloma - results from a phase 1 trial with the monoclonal immunoglobulin M antibody PAT-SM6.

Rasche L, Duell J, Castro IC, Dubljevic V, Chatterjee M, Knop S, Hensel F, Rosenwald A, Einsele H, Topp MS, Brändlein S.

Haematologica. 2015 Mar;100(3):377-84. doi: 10.3324/haematol.2014.117945.


Simultaneous binding of the anti-cancer IgM monoclonal antibody PAT-SM6 to low density lipoproteins and GRP78.

Rosenes Z, Mok YF, Yang S, Griffin MD, Mulhern TD, Hatters DM, Hensel F, Howlett GJ.

PLoS One. 2013 Apr 19;8(4):e61239. doi: 10.1371/journal.pone.0061239.


Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.

Plosker GL, Figgitt DP.

Drugs. 2003;63(8):803-43. Review.


A GRP78-Directed Monoclonal Antibody Recaptures Response in Refractory Multiple Myeloma with Extramedullary Involvement.

Rasche L, Menoret E, Dubljevic V, Menu E, Vanderkerken K, Lapa C, Steinbrunn T, Chatterjee M, Knop S, Düll J, Greenwood DL, Hensel F, Rosenwald A, Einsele H, Brändlein S.

Clin Cancer Res. 2016 Sep 1;22(17):4341-9. doi: 10.1158/1078-0432.CCR-15-3111.


Antithymocyte globulin induces complement-dependent cell lysis and caspase-dependent apoptosis in myeloma cells.

Ayuk FA, Fang L, Fehse B, Zander AR, Kröger N.

Exp Hematol. 2005 Dec;33(12):1531-6.


A murine monoclonal antibody directed against the carboxyl-terminal domain of GRP78 suppresses melanoma growth in mice.

de Ridder GG, Ray R, Pizzo SV.

Melanoma Res. 2012 Jun;22(3):225-35. doi: 10.1097/CMR.0b013e32835312fd.


P-selectin glycoprotein ligand-1 as a potential target for humoral immunotherapy of multiple myeloma.

Tripodo C, Florena AM, Macor P, Di Bernardo A, Porcasi R, Guarnotta C, Ingrao S, Zerilli M, Secco E, Todaro M, Tedesco F, Franco V.

Curr Cancer Drug Targets. 2009 Aug;9(5):617-25.


A new tumor-specific variant of GRP78 as target for antibody-based therapy.

Rauschert N, Brändlein S, Holzinger E, Hensel F, Müller-Hermelink HK, Vollmers HP.

Lab Invest. 2008 Apr;88(4):375-86. doi: 10.1038/labinvest.2008.2.


The human IgM antibody SAM-6 induces tumor-specific apoptosis with oxidized low-density lipoprotein.

Brändlein S, Rauschert N, Rasche L, Dreykluft A, Hensel F, Conzelmann E, Müller-Hermelink HK, Vollmers HP.

Mol Cancer Ther. 2007 Jan;6(1):326-33.


Targeting heat shock proteins on cancer cells: selection, characterization, and cell-penetrating properties of a peptidic GRP78 ligand.

Kim Y, Lillo AM, Steiniger SC, Liu Y, Ballatore C, Anichini A, Mortarini R, Kaufmann GF, Zhou B, Felding-Habermann B, Janda KD.

Biochemistry. 2006 Aug 8;45(31):9434-44.


Expression and function of Fas (APO-1/CD95) in patient myeloma cells and myeloma cell lines.

Westendorf JJ, Lammert JM, Jelinek DF.

Blood. 1995 Jun 15;85(12):3566-76.


Apoptosis and complement-mediated lysis of myeloma cells by polyclonal rabbit antithymocyte globulin.

Zand MS, Vo T, Pellegrin T, Felgar R, Liesveld JL, Ifthikharuddin JJ, Abboud CN, Sanz I, Huggins J.

Blood. 2006 Apr 1;107(7):2895-903.


Human natural immunoglobulin M antibodies induce apoptosis of human neuroblastoma cells by binding to a Mr 260,000 antigen.

David K, Ollert MW, Vollmert C, Heiligtag S, Eickhoff B, Erttmann R, Bredehorst R, Vogel CW.

Cancer Res. 1999 Aug 1;59(15):3768-75.


Myeloma cells express Fas antigen/APO-1 (CD95) but only some are sensitive to anti-Fas antibody resulting in apoptosis.

Shima Y, Nishimoto N, Ogata A, Fujii Y, Yoshizaki K, Kishimoto T.

Blood. 1995 Feb 1;85(3):757-64.


Elimination of drug-resistant myeloma tumor cell lines by monoclonal anti-P-glycoprotein antibody and rabbit complement.

Kulkarni SS, Wang ZM, Spitzer G, Taha M, Hamada H, Tsuruo T, Dicke KA.

Blood. 1989 Nov 1;74(6):2244-51.


Role of interleukin 16 in multiple myeloma.

Atanackovic D, Hildebrandt Y, Templin J, Cao Y, Keller C, Panse J, Meyer S, Reinhard H, Bartels K, Lajmi N, Sezer O, Zander AR, Marx AH, Uhlig R, Zustin J, Bokemeyer C, Kröger N.

J Natl Cancer Inst. 2012 Jul 3;104(13):1005-20. doi: 10.1093/jnci/djs257.


Effects of all-trans retinoic acid and antireceptor antibodies on growth and programmed cell death of human myeloma cells.

Taetle R, Dos Santos B, Akamatsu K, Koishihara Y, Ohsugi Y.

Clin Cancer Res. 1996 Feb;2(2):253-9.

Items per page

Supplemental Content

Support Center